Scandion Oncology hosted a virtual Capital Markets Day on September 8, 2021
Scandion Oncology will become a Phase III company
Watch a recording of the full event, where we launched our new focused clinical strategy with a clear path to market for SCO-101. We also presented an update from part 1 of the CORIST Phase II study, where we have documented a unique mode of action for SCO-101.
“Our path forward is built on a unique mode of action, and we have focused our clinical strategy to provide a clear route to registration and return on investments in RAS wild-type metastatic colorectal cancer. The ultimate outcome is to become a Phase III company as early as in 2023. We further see a huge opportunity for building on this platform knowledge, to broaden the clinical opportunities for SCO-101 in combination with Irinotecan and maximize business value” said President and CEO Bo Rode Hansen
Watch a replay of the event
Download Supporting Materials